Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached the details of the proposed schedule of Analyst/Institutional Investor meeting(s). Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached the details of the proposed schedule of Analyst/Institutional Investor meeting(s). Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the Regulation 30 of the SEBI Listing Regulations, please find attached copies of newspaper advertisement of Financial Results of the Company for the quarter and nine months ended on December 31, 2022, published in Financial Express and Jansatta on February 03, 2023. Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the audio recording of the Company's Conference Call dated February 02, 2023 with Investors/ Analysts for Q3 & 9M - FY23 is available on the Company's website at https://www.lalpathlabs.com/investors/investors-inside/quarterly-result
Dr. Lal Pathlabs Results Earnings Call for Q3FY23
Conference Call with Dr. Lal Pathlabs Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.
Dr Lal PathLabs Q3 net down 7% to Rs 54 cr, revenue declines to Rs 489 cr
Dr Lal PathLabs on Thursday said its consolidated profit after tax declined 7 per cent to Rs 54 crore for the December quarter. The company had reported a net profit of Rs 58 crore in the October-December quarter of the previous fiscal. Revenue also declined to Rs 489 crore for the period under review as compared with Rs 497 crore in the year-ago period, the company said in a regulatory filing. "We continue to focus on geographical expansion and strengthen our presence in Tier 2, Tier 3 towns. Our focus continues to take a higher market share in West and South markets by leveraging technology and promoting high-end super specialty test portfolios," Dr Lal PathLabs Managing Director Om Manchanda said. Shares of the company were trading 1.63 per cent down at Rs 2,019.15 apiece on the BSE. Q3FY23 Quarterly Result Announced for Dr. Lal Pathlabs Ltd.
Healthcare service firm Dr. Lal Pathlabs announced Q3FY23 results: Consolidated Q3FY23 vs Q3FY22: Non-Covid revenue increased by 9.1% in Q3FY23 to Rs 478 crore vs Rs 438 crore in Q3FY22. Total revenue declined by 1.5% in Q3FY23 to Rs 489 crore vs Rs 497 crore in Q3FY22. Covid and Allied contributed 2% to revenue in Q3FY23, and 12% in Q3FY22. Normalised EBITDA (after adjustment for stock-based compensation, CSR) for Q3FY23 is at Rs 122 crore (margins 24.9%) vs Rs 119 crore in the same quarter last year. Normalised PBT at Rs 89 crore, margins 18.2% vs Rs 90 crore in Q3 last year. Normalised PAT at Rs 66 crore, margins 13.5% vs Rs 66 crore in Q3 last year. Result PDF Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Change in Directorate
Please take note that the Board of Directors in their meeting held today i.e. February 02, 2023 approved the following item(s): Appointment of Mr. Arun Duggal (DIN: 00024262) as an Additional Director in the category of Independent Director of the Company for a term of three (3) years commencing from February 02, 2023 subject to approval of Shareholders of the Company through postal ballot process. Please also take note that Mr. Arun Duggal is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such Authority. Disclosure as required under Regulation 30 of the Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 is attached herewith as an Annexure- B. The Board Meeting commenced at 11:00 A.M and concluded at 02:00 P.M. Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith the Press Release for the Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2022. Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find attached a copy of Company''s Q3 & 9M FY23 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2022, approved by the Board of Directors in their meeting held on February 02, 2023.